News

The Allergenic Products Advisory Committee (APAC) voted seven to two that the efficacy data and eight to one that the safety data, along with other safeguards, are enough

The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing

Alder BioPharmaceuticals is involved in the discovery, development and commercialisation of novel therapeutic antibodies. As per terms of the deal, Lundbeck will begin a tender offer for all

The data demonstrate that, in two Phase I single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III (apoC-III) and ARO-ANG3 reduced plasma angiopoietin like protein 3

The company received notice today of the FDA approval of the individual IND application from the treating physician, Caroline Hastings, MD, pediatric hematologist/oncologist at the UCSF Benioff Children’s

The data from ASCLEPIOS I and II studies has demonstrated that ofatumumab was superior to Aubagio (teriflunomide) in patients with relapsing forms of MS (RMS). Both trials are

The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response

This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock. Additional consideration for up to $16 million in milestone

Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval